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a b s t r a c t
Differential scanning calorimetry was used to study the interaction of acyclovir and its prodrug
squalenoyl–acyclovir (obtained by conjugation of 1,1′,2-tris-nor-squalene acid (squaleneCOOH) with acy-
clovir) with biomembrane models made of DMPC multilamellar vesicles with the aim to verify whether a
stronger interaction of the prodrug with respect to the free drug can be obtained. Multilamellar vesicles
were prepared in the presence of increasing molar fractions of acyclovir, squaleneCOOH or prodrug and
the effect of the compounds on the thermotropic behavior of vesicles was researched, revealing no effect
of acyclovir but a strong effect of squaleneCOOH and prodrug. To evaluate if acyclovir, squaleneCOOH
and prodrug can be absorbed by the biomembrane model, an experiment was carried out in which the
considered compounds were left in contact with the biomembrane model and their eventual uptake was
evaluated analyzing the effect on the thermotropic behavior of the biomembrane model. A very small
uptake was revealed for all the compounds. To check the potential use of liposomes as a delivery system
for the prodrug, the biomembrane models were incubated with liposomes loaded with the compounds
and the compounds transferring from the loaded liposomes to the unloaded biomembrane model was





















Acyclovir [9-(2-hydroxyethoxymethyl)guanine; ACV], an
cyclic nucleoside analogue, has shown a potent antiviral activity.
t is known to inhibit the replication of herpes viruses including
erpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), varicella-
oster virus, and Epstein-Barr virus in cell cultures and in animals
Biron and Elion, 1980; O’Brien and Campoli-Richards, 1989; Li et
l., 2006).
Unfortunately, acyclovir has an oral bioavailability of only 20%
ecause of its low intestinal permeability (de Miranda and Blum,
983). The poor aqueous solubility and lipophilicity of acyclovir is
limitation to its pharmaceutical application. In order to overcome
hese limitations, a number of ACV prodrugs were synthesized.
alacyclovir, the l-valine ester prodrug of acyclovir, was synthe-
ized showing an oral bioavailability of 54% (Soul-Lawton et al.,
995). Dipeptide prodrugs of ACV were synthesized with the aim
o improve the ocular bioavailability of ACV after topical instil-
ation of an aqueous solution of the drug; the ACV prodrugs
∗ Corresponding author. Tel.: +39 095 221796; fax: +39 095 580138.
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showed to be stable, soluble and to possess in vivo antiviral efficacy
(Anand et al., 2003). Giammona et al. (1995) modified acyclovir
by acylation of the hydroxyl group in the side chain with suc-
cinic anhydride and the O-succinylacyclovir derivative obtained
was coupled to ,-poly(N-2-hydroxyethyl)-dl-aspartamide to
give a conjugate which showed a higher bioavailability after
oral and intravenous administration with respect to the free
acyclovir.
The enhancement of the lipophilic character of drugs was
related to their increased interaction with biomembrane mod-
els and then it can be used to improve their ability to enter the
cells (Pignatello et al., 2006) allowing to obtain useful information
in the correlation between the effect on the biomembrane mod-
els and the bioavailability. Recently, the acyclic isoprenoid chain
of squalene was coupled to gemcitabine to obtain the lipophilic
prodrug squalenoyl–gemcitabine whose interaction with biomem-
brane models was studied, giving indication of the improved
interaction of the prodrug with respect to the free gemcitabine
(Castelli et al., 2007).In this paper, the interaction of the prodrug squalenoyl–
acyclovir (SQACV) (obtained by conjugation of 1,1′,2-tris-nor-
squalene acid (squaleneCOOH) with acyclovir) (Fig. 1) with
biomembrane models was studied with the aim to verify if a differ-
ent interaction of the prodrug with respect to the free drug could




































Fig. 1. Squalenoyl–acyclovir, sq
e obtained. Experiments were carried out to evaluate the ability
f the prodrug to be absorbed by the biomembrane models, and to
heck the potential use of liposomes as a delivery system for the
rodrug.
Multilamellar vesicles (MLV) made of dimyristoylphosphatidyl-
holine (DMPC), used as biomembrane models, upon heating,
ndergo a phase transition from an ordered gel-like structure to a
isordered fluid-like structure at a well defined temperature (Tm)
nd with a defined enthalpy variation (H). This phase transition is
trongly affected by the presence of foreign molecules dissolved in
he phospholipid bilayer (Mouritsen and Bloom, 1984; Jorgensen et
l., 1991). The differential scanning calorimetry (DSC), which can
etect the phase transition of the MLV, was used (Mabrey-Gaud,
981; Bach, 1994; Huang and Li, 1999; Castelli et al., 2005, 2008).
The results can give information on the localization of the exam-
ned compounds inside the biomembrane and on the possible use
f liposomes as a suitable way to favour the transport of the prodrug
nto the biomembranes.
. Materials and methods
.1. Materials
Acyclovir (purity ≥99%) and squalene (purity = 98%) were
urchased from Sigma–Aldrich (Italy). 1,1′,2-tris-nor-squalene
ldehyde was obtained as previously reported (Ceruti et al., 2005).
QACV was obtained following the general method previously
escribed (Stella et al., 2005) by reaction of 1,1′,2-tris-nor-squalene
cid with acyclovir. It was completely pure, as revealed by 1H NMR
nd mass analysis. Concerning the possibility of obtaining either an
ster or an amide linkage between the squalenoyl chain and acy-
lovir, 1H NMR analysis revealed the presence of the free amino
roup at 6.57 ı (2 H, s, NH2), while the signal at about 12 ı of the
ypothetic amidic group was completely absent. It was also con-
rmed by comparison of 1H NMR spectra of ester and amide acetyl
erivatives of acyclovir reported in the literature (Matsumoto et
l., 1987). 1H NMR (DMSO): ı, 1.52–1.65 (18 H, m, allylic CH3),
.94–2.10 (16 H, m, allylic CH2), 2.13 (2 H, t, OCOCH2CH2), 2.31
2 H, t, OCOCH2), 3.63 (2 H, m, 3′-OCH2), 4.06 (2 H, m, 4′-CH2OCO),
.03–5.25 (5 H, m, vinylic CH), 5.32 (2 H, s, 1′-NCH2O), 6.57 (2 H, s,eCOOH and acyclovir structure.
NH2), 7.78 (1 H, s, 8-CH), 10.69 (1 H, s, cycle 1-NHCO). MS (CI): m/z
608 (M+, 100).
Synthetic l--dimyristoylphosphatidylcholine (DMPC)
(purity = 99%) was obtained from Genzyme (Switzerland). Lipids
were chromatographically pure as assessed by two-dimensional
thin layer chromatography. Lipid concentration was deter-
mined by the phosphorous analysis (Rouser et al., 1970). 50 mM
Tris(hydroxymethyl)-aminomethane (Tris) adjusted at pH 7.4 with
hydrochloric acid was used.
2.2. Differential scanning calorimetry
DSC was performed by using a Mettler TA Stare equipped with
a DSC 822e calorimetric cell and a Mettler STARe V 8.10 Software.
The reference pan was filled with Tris solution.
The sensitivity was automatically chosen as the maximum pos-
sible by the calorimetric system. The calorimetric system was
calibrated, in transition temperature and enthalpy changes, by
using indium, stearic acid and cyclohexane by following the proce-
dure of the Mettler TA STARe Software.
2.3. Compounds/MLV interaction
To study the interaction between the compounds and the
biomembrane model, MLV were prepared in the presence and
absence of increasing concentrations (0.00, 0.015, 0.03, 0.045, 0.06,
0.09, 0.12 and 0.15 molar fraction with respect the phospholipid) of
the studied compounds with two different procedures depending
on the compound. With regard to squaleneCOOH and SQACV, stock
solutions of DMPC (17.95 mg/ml), squaleneCOOH (2.98 mg/ml) and
SQACV (3.12 mg/ml) in chloroform were prepared and used straight
after. DMPC solution aliquots were put into glass tubes, in order
to have the same amount of lipid (7 mg), where aliquots of com-
pound solution were added to obtain increasing molar fractions
with respect to the lipid. The solvent was removed under nitrogen
flow and the resulting films were freeze-dried under vacuum. MLV
were obtained adding 168 l of Tris solution, heating at 37 ◦C for
1 min and shacking for 1 min, for three times. Afterward, MLV were
stored, 1 h, at 37 ◦C. As far as regard acyclovir, after the DMPC films
were freeze-dried, an exact amount of acyclovir solution in 50 mM





























ig. 2. Calorimetric curves, in heating mode, of DMPC MLV prepared in the presen
ractions.
ris (pH = 7.4), in order to have the considered molar fraction, was
dded.
Then, aliquots of 120 l (5 mg of lipid) of MLV aqueous
ispersion were transferred into a 160 l DSC aluminum pan,
ermetically sealed, and submitted to DSC analysis as follows: a
eating scan from 5 to 37 ◦C at the rate of 2 ◦C/min; a cooling scan
rom 37 to 5 ◦C at the rate of 4 ◦C/min; for at least three times.
o check the reproducibility of the results, the experiments were
epeated in triplicate; aliquots of all samples were then extracted
rom the calorimetric aluminum pans and used to determine, by
he phosphorous assay (Rouser et al., 1970), the exact amount of
hospholipids present in each sample.
.4. Permeation experiments
To study the ability of the examined compounds to go through
he aqueous medium and permeate the biomembrane model,
he following experiment was carried out: DMPC MLV aqueous
ispersion was left in contact with a fixed amount of chemical
powdered: acyclovir; oily: squaleneCOOH and SQACV) (to obtain a
.12 molar fraction with respect to the phospholipid vesicles aque-
us dispersion) placed in the bottom of the DSC pan. The pan was
ermetically sealed and then submitted to subsequent calorimetric
ycles according to the following procedure:
1) a scan from 5 to 37 ◦C, at the rate of 2 ◦C/min, to detect the inter-
action between the compound (which eventually dissolves in
the aqueous medium and transfers to phospholipid membrane)
and the biomembrane model during the heating of the sample;
2) 1 h, at 37 ◦C, to permit the compound to permeate the phos-
pholipid bilayers which, at this temperature, are in a disordered
state, the temperature being over the transition temperature of
the phospholipids employed;
3) a cooling scan between 37 and 5 ◦C, at the rate of 4 ◦C/min, to
go back to the starting step.
This procedure was run at least eight times to detect variations
n the temperature of the calorimetric peak (due to the uptake pro-
ess) occurring mainly during the period when the temperature is
ver the transition temperature.(A) acyclovir, (B) squaleneCOOH and (C) squalenoyl–acyclovir at increasing molar
2.5. Lipophilic carrier/biomembrane model transfer experiments
These experiments were carried out to evaluate the ability of the
compounds to transfer from a liposomal carrier (DMPC MLV loaded
with a determined amount of each compound) to the biomembrane
model (unloaded DMPC MLV). For this purpose, 60 l of DMPC MLV
loaded with a 0.12 molar fraction of compound was put into a 160 l
DSC pan and then 60 l of unloaded DMPC MLV aqueous dispersion
was added. The samples were hermetically sealed in the pan and
submitted to subsequent calorimetric cycles following the same
step procedure reported in the previous section.
3. Results and discussion
3.1. Compounds/MLV interaction
In order to improve the interaction of acyclovir with biomem-
brane models a prodrug was obtained by the conjugation of
squaleneCOOH to acyclovir. The interaction of the prodrug and
its precursors (squaleneCOOH and acyclovir) with biomembrane
model was studied. DMPC MLV were prepared in the presence of
increasing molar fractions of compounds and submitted to DSC
analysis. The recorded calorimetric curves were compared with
that of pure DMPC MLV (Fig. 2A–C). The calorimetric curve of pure
DMPC MLV presents, as known, a small peak (at about 17 ◦C), called
the pretransition peak, associated to the tilting of the phospholipid
lipophilic chains, and a main peak (at about 25 ◦C) which arises
from the gel–liquid crystalline (L–L) phase transition (Tenchov
and Koynova, 1996; Marsh, 1996; Walde, 2004). The variation of
the thermotropic parameters of the calorimetric curve indicates
that the compounds interact with the biomembrane models. The
calorimetric curves of the MLV prepared in the presence of increas-
ing molar fractions of acyclovir (Fig. 2A) do not show significant
variations with respect to that of DMPC MLV; it means that the acy-
clovir does not interact with the phospholipid bilayers, but, due to
its mainly hydrophilic nature (Majumdar et al., 2009), distributes
in the MLV aqueous layers or in the bulk phase. The calorimet-
ric curves in the presence of squaleneCOOH (Fig. 2B) show that
the pretransition peak disappears at the lowest molar fraction of
squaleneCOOH present, whereas the main peak is shifted toward
lower temperature and broadens, giving indication of the strong
76 M.G. Sarpietro et al. / International Journal of Pharmaceutics 382 (2009) 73–79
Fig. 3. Transition temperature, as T/T0m, of DMPC MLV prepared in the presence













































Fig. 4. Enthalpy variation, as H/H0, of DMPC MLV prepared in the presence of
that in its extended form is as large as 29 Å (Simon et al., 1977).
Such a length is far longer than that of common phospholipids like
DPPC and DMPC which form bilayers of about 20 Å per single mono-
layer (Nagle and Tristam-Nagle, 2000). Indeed, it is well-known
that the most famous squalene-derivative, the cholesterol, easilys a function of compound molar fraction. T = Tm − T0m, where Tm is the transition
emperature of DMPC MLV prepared in the presence of compound and T0m is the
ransition temperature of DMPC MLV.
nteraction of this compound with the MLV phospholipid bilay-
rs. Moreover, a phase separation is strongly evident starting from
.09 molar fraction, which could be due to a not uniform distri-
ution of squaleneCOOH among the phospholipid molecules and,
ence, to the formation of squaleneCOOH rich and squaleneCOOH
oor regions (Estep et al., 1978; Bruggemann and Melchior, 1983).
he calorimetric curves of DMPC MLV prepared in the presence
f SQACV are showed in Fig. 2C. SQACV causes the pretransition
eak to completely disappear at all the used molar fractions and
he main peak to shift and broaden as its molar fraction increases.
his is an evidence of the occurring interaction between SQACV
nd DMPC MLV. Differently from squaleneCOOH, SQACV does not
ause phase separation, suggesting that this compound uniformly
istributes among phospholipid molecules. This is in agreement
ith the results obtained by Mavromoustakos et al. (1996) which
tudied the effect of cannabinoids on phospholipid bilayers and
bserved that the more hydrophilic the molecule, the lesser its
endency to produce domains.
A comparison of the effect of SQACV with respect to those of
ts precursors on the biomembrane model can be obtained plot-
ing the Tm, the H and the peak width (width at peak half height,
T1/2) as a function of the compounds molar fraction present in
he MLV aqueous dispersion. In Fig. 3, the Tm is plotted as T/T0m
T = Tm − T0m, Tm being the transition temperature of DMPC MLV
repared in the presence of compound and T0m being the transi-
ion temperature of pure DMPC MLV). Acyclovir causes just small
m variation, SQACV, and even more, squaleneCOOH cause the
m decrease. The decrease of the Tm reflects the solubility of the
olecule in the fluid phase rather than in the gel phase. In fact,
olecules with kinks are expected to pack easier in the fluid mem-
rane with the disordered aliphatic chains of the lipids than in
he gel state with the straight ordered lipid acyl chains differ-
ntly from molecules with straight chains, like stearic acid, which
nteract more favourably with the gel phase of the lipid bilayer
Ortiz and Gomez-Fernandez, 1987; Peters et al., 2009). The H val-
es, as H/H0 (H = H − H0, with H being the enthalpy
ariation of DMPC MLV prepared in the presence of compound
nd H0 being the enthalpy variation of pure DMPC MLV), are
hown in Fig. 4. Acyclovir does not affect the H, SQACV, and
ven more, squaleneCOOH lead a H depression. The T1/2 values
Fig. 5) reveal strong differences among the compounds; in fact,
hile acyclovir seems not to perturb the T1/2, squaleneCOOH andacyclovir, squaleneCOOH and squalenoyl–acyclovir at increasing molar fraction as a
function of compound molar fraction. H = H − H0, where H is the enthalpy
variation of DMPC MLV prepared in the presence of compounds and H0 is the
enthalpy variation of pure DMPC MLV.
SQACV produce the T1/2 increase. All these results indicate that
squaleneCOOH and SQACV have a fluidizing effect on the phospho-
lipid bilayer, interact with the hydrophobic acyl chains and cause a
reduction of the cooperativity of the C1–C8 region of the bilayer
(Jain and Wu, 1977; Raudino and Castelli, 1998; Huang and Li,
1999; Wolka et al., 2004). And then, while acyclovir does not insert
in the phospholipid bilayers, squaleneCOOH and SQACV localize
in the bilayers. The different effect exerted by squaleneCOOH and
SQACV on the transition phase can give information on their local-
ization in the phospholipid bilayers. The stronger effect exerted
by squaleneCOOH suggests that it enters into the bilayers more
deeply than SQACV does. SqualeneCOOH could localize in a way
that the polar part is next the phospholipid polar head and the
remaining part parallel to the phospholipid apolar tails. This con-
jecture is not in contrast with the apparent length of squaleneCOOHFig. 5. Peak width (width at half height peak, T1/2) of DMPC MLV prepared in the
presence of acyclovir, squaleneCOOH and squalenoyl–acyclovir at increasing molar
fraction as a function of compound molar fraction.
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as a function of the calorimetric scans and shown in Fig. 7. Acy-
clovir does not cause any transition temperature variation; then
no interaction between acyclovir and MLV occurs. SqualeneCOOH
and SQACV cause a negligible decrease of the transition tempera-
Fig. 7. Transition temperature, as T/T0m, of DMPC MLV left in contact with acy-ig. 6. Calorimetric curves, in heating mode, of DMPC MLV left in contact with (A) ac
cans (increasing incubation periods). Curve X = 0.12 belongs to DMPC MLV prepare
btained if the compound was completely absorbed by the MLV.
ccommodates into lipid bilayers of different thickness. Thus, we
ay suggest three different explanations for the squaleneCOOH
ccommodation in the lipid bilayer: (a) the hydrophobic back-
one of squalene assumes a coiled conformation similar to that
f its condensed derivative, the cholesterol. In this configuration,
he polar head of squaleneCOOH is in contact with water while
ts tail basically is parallel to those of surrounding lipids. Obvi-
usly, squaleneCOOH must pay a small entropy cost in order to
dopt a particular rigid conformation. (b) Some additional space to
ccommodate the long molecules may be gained if squaleneCOOH
ssumes a tilted conformation with respect to the membrane plane.
ecent Molecular Dynamics simulations have confirmed such a
ossibility, evidencing very tilted cholesterol configuration inside
he lipid bilayer (Kucerka et al., 2008). (c) Foreign molecules may
hange the order parameter of the surrounding lipids and, conse-
uently, the whole thickness of the lipid bilayer. Such a strategy is
dopted by cholesterol that can be easily accommodated into bilay-
rs of different thickness: bilayers made up of long lipids become
hinner (McIntosh, 1978; Gallova et al., 2004) while those consti-
uted by short saturated (McIntosh, 1978) or unsaturated lipids
Kucerka et al., 2007) become thicker. In SQACV, the squalenoyl
oiety could stay among the phospholipid tails, whereas the acy-
lovir moiety could protrude in the aqueous environment with a
mall contribution to the prodrug effect on the phospholipid ther-
otropic behavior.
.2. Permeation experiments
Once the interaction of the compounds with the biomem-
rane model was studied, the absorption of the prodrug by the
iomembrane models was evaluated; for this reason we performed
xperiments in which the compound (at 0.12 molar fraction)
nd the MLV were incubated at 37 ◦C and the interaction com-
ound/MLV was monitored as soon as before the incubation and
t intervals of 1 h; for completeness, experiments with neat acy-
lovir and squaleneCOOH were also performed. If the compound,
eft in the same aqueous environment of the MLV, was absorbed by
hem, then, a gradual modification of calorimetric curves should
esult and if the absorption was complete a curve similar (in shaper, (B) squaleneCOOH and (C) squalenoyl–acyclovir at 0.12 molar fraction, at different
he presence of compounds at 0.12 molar fraction and is the curve which should be
and thermodynamic parameters) to that obtained from the anal-
ysis of the MLV prepared in the presence of the compound at
0.12 molar fraction should be reached. The obtained calorimetric
curves were, then, compared with that of the pure DMPC MLV and
that of the MLV prepared in the presence of a 0.12 molar fraction
of compound and are shown in Fig. 6A–C. As expected, acyclovir
does not cause modification in the calorimetric curves. Squalene
and SQACV cause just a negligible effect on both the pretransi-
tion peak and the main peak. The results are reported, as T/T0m,clovir, squaleneCOOH and squalenoyl–acyclovir at 0.12 molar fraction, as a function
of the calorimetric scans. T = Tm − T0m, where Tm is the transition temperature of
DMPC MLV prepared in the presence of compound and T0m is the transition tem-
perature of pure DMPC MLV. r values are the transition temperature of DMPC MLV
prepared in the presence of compounds at 0.12 molar fraction and represent the
maximum interaction between compounds and MLV.



































ig. 8. Calorimetric curves, in heating mode, of DMPC MLV (unloaded MLV) left in c
qualenoyl–acyclovir at 0.12 molar fraction (loaded MLV), at increasing incubation
ure but the effect exerted by SQACV is a little bigger with respect
o squaleneCOOH. It indicates that SQACV is absorbed more than
qualeneCOOH by the biomembrane models. SqualeneCOOH does
ot dissolve in the aqueous medium and, consequently, cannot
e absorbed by the MLV. SQACV, being more hydrophilic than
qualeneCOOH, dissolves, even if in a small amount, in the aqueous
edium, reaches the MLV surface and goes inside the phospholipid
ilayers.
.3. Lipophilic carrier/biomembrane model transfer experiments
The second kind of experiments was aimed at evaluating the
apability of the compounds to be transferred from a lipophilic car-
ier to the biomembrane models. For this purpose, each compound
0.12 molar fraction) loaded MLV (which can mimic a lipophilic
arrier) were left to incubate for increasing periods of 1 h, at 37 ◦C,
ith unloaded MLV (which mimic the receptor biomembrane mod-
ls). The compound transfer was evaluated by the calorimetric
cans carried out during the first heating and after each incuba-
ion period of 1 h (including also the periods of heating and cooling
bove the transition temperature). If the transfer of the compounds
rom loaded liposomes to unloaded liposomes happened, a flux of
ompound should take place that will stop only when the com-
ound concentration equilibrium between the loaded MLV and
he initially unloaded MLV is reached. At this stage the Tm value
ill be the same as that of MLV loaded with a 0.06 molar fraction
f compound prepared as described in “Compounds/MLV interac-
ion”. The calorimetric curves (Fig. 8A–C) are compared with that
f the sample that were left in incubation (loaded and unloaded
LV) and with that of the curve of the MLV prepared in the pres-nce of compound at 0.06 molar fraction. In the case of acyclovir
Fig. 8A) no modification, as expected, are visible in the calorimetric
urves, in fact acyclovir, as seen in the experiments on the inter-
ction compounds/MLV, does not interact with the phospholipid
ilayers. Concerning squaleneCOOH (Fig. 8B), the first calorimet-t with DMPC MLV prepared in the presence of (A) acyclovir, (B) squaleneCOOH, (C)
s.
ric curve (1st scan), obtained from the heating of the sample to
the first isothermal period, shows: a pretransition peak (at about
17 ◦C), a broad small peak (from about 20 to 24 ◦C) belonging to
the loaded MLV, and a main peak (at about 25 ◦C) belonging to the
unloaded MLV. In the curves of the successive scans (at increas-
ing incubation times), the pretransition peak and the broad small
peak gradually decrease, the main peak undergoes a very small shift
towards lower temperature indicating that squaleneCOOH trans-
fers from the lipophilic carrier to the biomembrane models. The
transfer is very slow and incomplete; in fact the molecule, due to
its lipophilic nature and, then, to its high affinity for the phospho-
lipid molecules, remains in the MLV bilayers. With regard to SQACV
(Fig. 8C), in the first calorimetric curve (1st scan) three regions are
present: a pretransition peak (at about 17 ◦C), a well defined shoul-
der (at about 23.5 ◦C) due to the loaded MLV, and a main peak (at
about 25 ◦C) due to the unloaded MLV; in the successive scans, as
the incubation time passes, the pretransition peak and the shoul-
der decrease almost disappearing whereas the main peak shifts
towards lower temperature meaning that SQACV is able to trans-
fer, even if not completely, from the carrier to the biomembrane
models.
Summarizing the results, it can be concluded that the conju-
gation of squalene to acyclovir with the formation of a lipophilic
prodrug permits a strong interaction with the biomembrane mod-
els; the prodrug is scarcely taken up by the biomembrane models
but when loaded in a lipophilic carrier the prodrug is gradually
transferred to the biomembrane models. These results could help to
achieve the desired physicochemical characteristics for the prepa-
ration of effective types of liposomal carriers.Acknowledgments
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